Next Generation Tumor-Diagnostik-Reference-Cited by-同舟云学术

Next Generation Tumor-Diagnostik

Published:2021-09-16 Issue:3 Volume:19 Page:230-232
ISSN:2198-1310
Container-title:Liquid Biopsy in der Onkologie
language:de
Short-container-title:TD

Author:

Loewe Robert P.,Kirchner Benedikt,Grätz Christian,Bui Maria L.U.,Pfaffl Michael W.

Publisher

Trillium GmbH Medizinischer Fachverlag

Reference16 articles.

1. 1. Hugenschmidt H, Labori KJ, Borgen E, Brunborg C, Schirmer CB, Seeberg LT et al. Preoperative CTC-Detection by CellSearch® Is Associated with Early Distant Metastasis and Impaired Survival in Resected Pancreatic Cancer. Cancers (Basel) 2021;13(3). https://doi.org/10.3390/cancers13030485.

2. 2. Millner LM, Linder MW, Valdes R. Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Ann Clin Lab Sci 2013;43(3):295–304.

3. 3. Rushton AJ, Nteliopoulos G, Shaw JA, Coombes RC. A Review of Circulating Tumour Cell Enrichment Technologies. Cancers (Basel) 2021;13(5). https://doi.org/10.3390/cancers13050970.

4. 4. Tabernero J, Lenz H-J, Siena S, Sobrero A, Falcone A, Ychou M et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. The Lancet Oncology 2015;16(8):937–48. https://doi.org/10.1016/S1470-2045(15)00138-2.

5. 5. Toledo RA, Cubillo A, Vega E, Garralda E, Alvarez R, La Varga LU de et al. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget 2017;8(21):35289–300. https://doi.org/10.18632/oncotarget.13311.